News & Updates
Filter by Specialty:
Post-exposure doxycycline prevents STIs in MSM, TGW with HIV or on PrEP
Doxycycline, taken with 72 hours of unprotected sex, could prevent sexually transmitted infections (STIs) in men who have sex with men (MSM) or transgender women (TGW) who are either living with HIV (PLHIV) or are receiving pre-exposure prophylaxis (PrEP), according to a study presented at AIDS 2022.
Post-exposure doxycycline prevents STIs in MSM, TGW with HIV or on PrEP
05 Oct 2022
Niraparib maintenance boosts PFS in advanced ovarian cancer
Maintenance therapy with the PARP* inhibitor niraparib led to a sustained and durable progression-free survival (PFS), regardless of biomarker status, in patients with primary advanced ovarian cancer who responded to platinum-based chemotherapy, an updated analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial has shown.
Niraparib maintenance boosts PFS in advanced ovarian cancer
05 Oct 2022
Deucravacitinib bestows benefits in Asian patients with plaque psoriasis
The benefit of deucravacitinib in moderate to severe plaque psoriasis was demonstrated in a population of Asian patients, according to results of the phase III POETYK PSO-3 trial.
Deucravacitinib bestows benefits in Asian patients with plaque psoriasis
04 Oct 2022
POSEIDON updates boost treatment potential of tremelimumab-durvalumab-CT for mNSCLC
In the updated analysis of the POSEIDON trial presented at ESMO 2022, the combination regimen comprising tremelimumab, durvalumab, and chemotherapy (T+D+CT) used in the first-line setting conferred long-term overall survival (OS) benefit in individuals with metastatic non-small-cell lung cancer (mNSCLC).
